Cardiac Involvement in Neurosarcoidosis: A Single-Center Investigation
Sama Noroozi GilandehiKa-Ho WongTrieste FrancisMelissa A WrightJennifer LordJosef StehlikLine KemeyouTammy SmithStacey L ClardyPublished in: Neurology(R) neuroimmunology & neuroinflammation (2024)
In this cohort, 12% of patients with NS also had confirmed CS. In addition, these patients had a high burden of cardiovascular disease not directly attributed to sarcoidosis. Our data suggest that patients with NS require comprehensive cardiac evaluation. Future studies are needed to clarify the extent of the direct contribution of granulomatous inflammation on the cardiovascular system from the indirect contribution of treatments such as glucocorticoids that lead to increased risk of cardiovascular disease in sarcoidosis.
Keyphrases
- cardiovascular disease
- end stage renal disease
- left ventricular
- newly diagnosed
- ejection fraction
- chronic kidney disease
- oxidative stress
- dengue virus
- type diabetes
- prognostic factors
- peritoneal dialysis
- heart failure
- cardiovascular events
- risk factors
- rheumatoid arthritis
- patient reported outcomes
- machine learning
- systemic sclerosis
- cardiovascular risk factors
- current status
- interstitial lung disease
- zika virus
- metabolic syndrome
- clinical evaluation